Pharmaceutical

Q&A: Increasing awareness around digital therapeutics key to realising full potential

Andy Molnar, CEO of the Digital Therapeutics Alliance, discusses the latest trends and challenges in the digital therapeutics space.

Mar 16, 2024 - 00:00
Q&A: Increasing awareness around digital therapeutics key to realising full potential
Andy Molnar, CEO of the Digital Therapeutics Alliance, discusses the latest trends and challenges in the digital therapeutics space.
Read the original article

Tags:

Previous Article

FDA approves BeiGene’s TEVIMBRA for oesophageal cancer

Next Article

Xcovery edges closer to FDA approval for NSCLC ALK inhibitor

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MSD secures worldwide license for LaNova’s LM-299

MSD secures worldwide license for LaNova’s LM-299

Nov 15, 2024

STAT+: Amgen’s rheumatoid arthritis drug Enbrel targeted for first-in-the-nation price limit in Colorado

STAT+: Amgen’s rheumatoid arthritis drug Enbrel targete...

Feb 23, 2024

No pain data yet from Vertex, and sky high deal expectations at JPM 2024

No pain data yet from Vertex, and sky high deal expecta...

Jan 8, 2024